{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Performance status 0"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Performance status 1"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Performance status 2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.","groups":[{"description":"Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Gleevec"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Initial Performance Status","type":"SECONDARY","unitOfMeasure":"Participants"}